Priorix

Sponsor:

GlaxoSmithKline Australia

Administration route:

Intramuscular injection, Subcutaneous injection

Vaccine group:

Combination vaccines

Registered for use in people aged ≥12 months.

— measles-mumps-rubella combination vaccine

Lyophilised pellet in a monodose vial with a pre-filled diluent syringe.

Each 0.5 mL reconstituted dose contains:

≥10^3.0 cell culture infectious dose 50% (CCID₅₀) of live attenuated measles virus (Schwarz strain)
≥10^3.7 CCID₅₀ of live attenuated mumps virus (RIT 4385 strain, derived from the Jeryl Lynn strain)
≥10^3.0 CCID₅₀ of live attenuated rubella virus (Wistar RA 27/3 strain)
lactose
neomycin
sorbitol
mannitol

For full details, refer to the product information and consumer medicine information sheets for Priorix vaccine available on the TGA website.

Last updated:

4 June 2018

Last reviewed:

4 June 2018

Definitions